Cleveland Clinic, University Hospitals to Use $1M Gift for Sequencing Underserved Cancer Patients

“Cleveland Clinic and University Hospitals have received a $1 million donation to support genome sequencing for cancer patients across the Northeast Ohio region.

“The gift will be dispersed evenly between both institutions over three- years to establish the Rosalie and Morton Cohen Family Memorial Genomics Fund, Cleveland Clinic said on Wednesday.

“The fund will expand access to genomic sequencing for underserved populations in the region that have some of the highest mortality rates in the state.”

Learn more about personalized medicine.


Landmark Gift of $100 Million from the Marie-Josée and Henry R. Kravis Foundation Will Support Groundbreaking Approach to Precision Oncology at Memorial Sloan Kettering Cancer Center

“Memorial Sloan Kettering Cancer Center today launched an ambitious initiative to improve cancer care and research through genomic analysis. The new program will reshape clinical trials and speed the translation of novel molecular discoveries into routine clinical practice…

“ ‘Progress in our understanding of the biology of cancer has completely shifted the way we think about and treat cancer,’ says Craig Thompson, MD, MSK President and CEO. ‘We’re moving away from the concept of treating cancer as many different types of the same disease and toward treating each person’s cancer as its own unique disease. Now, thanks to the inspiring generosity of the Marie-Josée and Henry R. Kravis Foundation, we will be able to expand and intensify this effort, ushering in what will truly be a new era of precision medicine.’ ”

Editor’s note: Learn more about personalized approaches to cancer treatment.


Landmark Gift of $100 Million from the Marie-Josée and Henry R. Kravis Foundation Will Support Groundbreaking Approach to Precision Oncology at Memorial Sloan Kettering Cancer Center

“Memorial Sloan Kettering Cancer Center today launched an ambitious initiative to improve cancer care and research through genomic analysis. The new program will reshape clinical trials and speed the translation of novel molecular discoveries into routine clinical practice…

“ ‘Progress in our understanding of the biology of cancer has completely shifted the way we think about and treat cancer,’ says Craig Thompson, MD, MSK President and CEO. ‘We’re moving away from the concept of treating cancer as many different types of the same disease and toward treating each person’s cancer as its own unique disease. Now, thanks to the inspiring generosity of the Marie-Josée and Henry R. Kravis Foundation, we will be able to expand and intensify this effort, ushering in what will truly be a new era of precision medicine.’ ”

Editor’s note: Learn more about personalized approaches to cancer treatment.


Landmark Gift of $100 Million from the Marie-Josée and Henry R. Kravis Foundation Will Support Groundbreaking Approach to Precision Oncology at Memorial Sloan Kettering Cancer Center

“Memorial Sloan Kettering Cancer Center today launched an ambitious initiative to improve cancer care and research through genomic analysis. The new program will reshape clinical trials and speed the translation of novel molecular discoveries into routine clinical practice…

“ ‘Progress in our understanding of the biology of cancer has completely shifted the way we think about and treat cancer,’ says Craig Thompson, MD, MSK President and CEO. ‘We’re moving away from the concept of treating cancer as many different types of the same disease and toward treating each person’s cancer as its own unique disease. Now, thanks to the inspiring generosity of the Marie-Josée and Henry R. Kravis Foundation, we will be able to expand and intensify this effort, ushering in what will truly be a new era of precision medicine.’ ”

Editor’s note: Learn more about personalized approaches to cancer treatment.


New Test Could Accurately Predict Prostate Cancer Recurrence

“Researchers have created a test that they say can predict whether a man is at high risk of prostate cancer recurrence.

“The research team, led by Prof. Robert Bristow of the Princess Margaret Cancer Centre and the University of Toronto, both in Canada, presented their findings at the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna, Italy.

“For men with cancer confined to the prostate, surgery and precision radiotherapy are the primary treatments. However, Prof. Bristow explains that during initial treatment, whether the cancer has spread outside the prostate often goes undetected. This means the cancer will return in 30-50% of patients.”


Researchers Intensify Efforts to Solve Mysteries of Exceptional Responders

“Exceptional responders — those patients with cancer who demonstrate sustained benefit from a therapy on which almost all others fail — have been observed in clinical trials for decades.

“ ‘This is the basis of the urban legend story that everyone has heard — someone was given 2 months to live, but was given a drug and had a miraculous recovery,’ William C. Hahn, MD, PhD, chief of the division of molecular cellular oncology at Dana-Farber Cancer Institute, told HemOnc Today.

“Because of recent strides in genomic sequencing, however, the phenomenon has evolved from a series of unexplained individual success stories into a collection of tremendously valuable case studies.”


Researchers Intensify Efforts to Solve Mysteries of Exceptional Responders

“Exceptional responders — those patients with cancer who demonstrate sustained benefit from a therapy on which almost all others fail — have been observed in clinical trials for decades.

“ ‘This is the basis of the urban legend story that everyone has heard — someone was given 2 months to live, but was given a drug and had a miraculous recovery,’ William C. Hahn, MD, PhD, chief of the division of molecular cellular oncology at Dana-Farber Cancer Institute, told HemOnc Today.

“Because of recent strides in genomic sequencing, however, the phenomenon has evolved from a series of unexplained individual success stories into a collection of tremendously valuable case studies.”


Researchers Intensify Efforts to Solve Mysteries of Exceptional Responders

“Exceptional responders — those patients with cancer who demonstrate sustained benefit from a therapy on which almost all others fail — have been observed in clinical trials for decades.

“ ‘This is the basis of the urban legend story that everyone has heard — someone was given 2 months to live, but was given a drug and had a miraculous recovery,’ William C. Hahn, MD, PhD, chief of the division of molecular cellular oncology at Dana-Farber Cancer Institute, told HemOnc Today.

“Because of recent strides in genomic sequencing, however, the phenomenon has evolved from a series of unexplained individual success stories into a collection of tremendously valuable case studies.”


Fight Against Prostate Cancer Takes a Page Out of the Breast-Cancer Approach

“In a bid to improve treatment for men with high-risk prostate cancer, some researchers want to take a page from the playbook for breast cancer. Medical scientists are working to develop strategies for treating prostate tumors that are tailored to individual patients, as is currently done for many women with breast cancer. Fresh advances in the understanding of prostate cancer suggest that some men with a high-risk form of the disease might benefit from more aggressive treatment.”